尼扎替丁减轻第二代抗精神病药物所致体质量增加的 Meta 分析

Meta-analysis of nizatidine reduces second generation antipsychotics induced weight gain

目的：探讨尼扎替丁减轻第二代抗精神病药物（SGAs）所致精神分裂症患者体质量增加的干预效果。方法计算机检索 PubM ed、EBSCO、EM base、Cochrane Library、中国期刊全文数据库（CNKI）、万方数据库和维普中文科技期刊数据库（VIP），纳入关于尼扎替丁减轻SGAs所致体质量增加的随机对照研究，检索时限从建库起至2015年5月，手工检索相关的已发表文献。由两位研究者独立进行文献筛检、资料提取和方法学质量评价后，采用RevMan 5．1和Stata 12．0软件进行Meta分析。结果纳入4篇随机对照试验（RCTs ），共292例患者（治疗组118例，对照组174例），观察时间为（14.6±3．8）周。Meta分析结果显示，干预结束时尼扎替丁组体质量、体质量指数（BMI）和瘦素水平均低于对照组，差异均有统计学意义（P ＜0．05）；干预结束时两组的临床疗效比较（SMD ＝0．02，95％ CI ＝－0．22～0．26），差异无统计学意义（P ＞0．05）。结论尼扎替丁能有效地减轻SGAs（奥氮平和喹硫平）所致的体质量增高。

Objective To assess the intervention effect of nizatidine on attenuating second -gener‐ation antipsychotics （SGAs） induced weight gain in patients with schizophrenia .Methods The random‐ized controlled trials （RCTs） about nizatidine for weight loss in patients with SGAs ,（published until September 2013） were searched in the PubMed ,EBSCO ,EMbase ,Cochrane Library ,CNKI ,WanFang Database and VIP .We also hand -searched some published references .Two reviewers independently screened the literatures ,extracted the data ,and evaluated the methodology .Meta-analysis was conduc‐ted by RevMan 5 .1 and Stata 12 .0 software .Results The total 4 RCTs involving 292 patients [nizatidine group （n= 118）;control group （n= 174）] were included .The treatment period was 14 .6 ± 3 .8 weeks .Meta-analysis showed that the nizatidine group was significantly superior to the control group in lessen body weight ,BMI ,and leptin levels （P〈 0 .05） .However ,there was no significant difference in clinical efficacy be‐tween two groups （SMD = 0 .02 ,95% CI = -0 .22 -0 .26 , P 〉 0 .05） .Conclusions Nizatidine can effectively attenuate SGAs （olanzapine and quetiapine） induced weight gain .